Personalized. Preventive. Precise.

ATCOR creates innovative technologies that enable clinicians to manage patients’ hypertension with more personalized and precise treatment plans.

Hypertension is the underlying cause of cardiovascular disease—the #1 killer of people in the developed world.

Our SphygmoCor XCEL system measures central blood pressure, central arterial pressure waveform, and pulse wave velocity—all noninvasively.

SphygmoCor is FDA-cleared, CE-marked, and approved by China FDA. It is a reimbursable technology, available through a variety of guaranteed EZ acquisition programs.

More than 4,500 SphygmoCor systems are currently deployed worldwide at luminary teaching hospitals, specialist practices, research institutions, and in various clinical trials with top-tier pharmaceutical companies.

Our technology is featured in over 1,400 peer-reviewed publications in leading medical journals.

Clinical Use Cases

Our central arterial pressure waveform analysis provides clinicians with richer prognostic and diagnostic information for earlier, more targeted cardiovascular interventions for a variety of serious medical conditions.

COPD - Heart Failure - Renal Disease - Hypertension - Diabetes

Why Central Blood Pressure?

Cardiovascular disease is the leading cause of death worldwide—and elevated blood pressure is the clearest modifiable risk factor. Extensive research shows that central blood pressure measurement and waveform analysis are superior methods for managing patients with hypertension and cardiovascular disease.

Central blood pressure is the pressure experienced by the heart, brain, kidneys, and other central organs. It is really important to understand that central pressures can be very different from pressures in the upper arm—at the brachial artery—where blood pressure is typically measured.

Noninvasive central blood pressure (NcBP) provides patient-specific information about what is causing hypertension. This can have significant impact on treatment decisions. In fact, many patients may be over-treated or under-treated if medication and other therapeutic decisions are based solely on brachial blood pressures.